Business Wire

IBSA

Share
IBSA’s Initiatives Focused on the Patients’ Experience and a Greater Knowledge of Thyroid Dysfunctions

The patient satisfaction and quality of life of people being treated for hypothyroidism are of considerable interest, and are very often associated with a lack of confidence and trust and with negative experiences with health care professionals. It is precisely on this aspect that IBSA would like to focus the general attention on the occasion of the International Thyroid Awareness Week (ITAW), celebrated each year from May 25th to 31st, that aims at raising awareness of the prevention of thyroid diseases and awareness of early recognition and adequate treatment of thyroid disorders to prevent further complications.

Thyroid dysfunctions are quite common: it is estimated that over 1.5 billion people worldwide are at risk of thyroid disorders, and that hypothyroidism alone affects 5% of the world’s population1, with a greater incidence among women. Early diagnosis is essential in the treatment of these conditions, but – since symptoms are almost always nonspecific (weight gain, decreased energy and malaise, sensitivity to cold, mood swings, to name but a few) – a timely and correct identification of the disease is difficult, compromising the quality of life of the people affected.

To shed some light on the matter, on May 25 at 2:00 pm (CEST), IBSA – in collaboration with Thyroid Federation International (TFI), the international organisation of patients with thyroid diseases – promotes the webinarPatient-centered approach to hypothyroidism” (registrations at this link), a meeting aimed at giving voice to some of the issues that often trouble hypothyroid patients, impacting their satisfaction with the management of the disease, as well as their quality of life.

These aspects have been evaluated in particular by the surveyE-MPATHY” (E-Mode Patient self-Assessment of THYroid therapy) – carried out by TFI with the contribution of IBSA – which electronically enrolled a total of 3,915 hypothyroid patients from 68 countries2. The survey investigated the impact of hypothyroidism on the patients’ satisfaction with the quality of daily life and their experiences with doctors and healthcare professionals: it emerged that about 50% of the interviewees are dissatisfied with the management and treatment of the disease, mostly due to negative experiences with their doctor, characterised by a severe lack of trust; and that for the majority (nearly 70%) hypothyroidism had negatively affected their daily life2.

Some aspects of hypothyroidism management continue to pose a challenge. Because symptoms are often non-specific, many people living with a thyroid disorder are currently undiagnosed and they can spend many years struggling with a poor quality of life before getting a diagnosis. However, another consequence of the non-specific symptomatology is unfortunately that up to 10-15% of those with a diagnosis of hypothyroidism do not fulfil the biochemical requirements for such a diagnosis. Importantly, at least 5-10% of those treated with thyroid hormones report a poor QoL, due to persistence of symptoms of hypothyroidism”, commented Laszlo Hegedüs, Emeritus Professor at the Department of Endocrinology in Odense (Denmark) and former president of the European Thyroid Association (ETA). “Increasing the awareness of thyroid disorders could stimulate patients to talk with their doctors, because only in the hands of a healthcare professional thyroid disorders can be well managed, which includes avoiding under- as well as over-substitution with thyroid hormone”.

Faced with a condition such as hypothyroidism – and the difficulty in recognising it – patients need even more to be listened to and accompanied along their diagnosis and treatment path”, pointed out Ashok Bhaseen, Presidente of Thyroid Federation International. “As a Patient Organisation, we become the spokespersons for these still unsatisfied needs; our task is to echo them among doctors, institutions and the whole community, in order to improve the quality of life of the people living with thyroid dysfunction”.

To raise awareness of these conditions and support patients in their daily management, IBSA launchesFeel Thyroid”, the international campaign aimed at raise awareness on hypothyroidism in particular. Learning to recognise the symptoms of the disease and discussing it with the doctor as soon as possible are critical steps in order to obtain an early diagnosis or to improve the management of the disease, defined on the basis of one’s specific needs.

All the contents of the Feel Thyroid campaign are accessible on the dedicated platform www.feelthyroid.com, which offers useful information on the condition and, above all, interactive tools which allow to stimulate the patients in their daily management and to draw ideas for a proactive discussion with their doctor. The goal is to improve people’s quality of life favouring a greater collaboration and synergy between patient and specialist, in order to address hypothyroidism, promote dialogue and identify the most appropriate treatment.

IBSA has always been attentive to the Person: helping improve the treatment path and the quality of life of the many patients who have to live with a thyroid disease every day is part of our commitment”, explained Marialuisa Fino, Therapeutic Area Manager Endocrinology at IBSA. “We are pleased to announce the international launch of Feel Thyroid, a campaign born from listening to people’s real needs and designed to support them in their daily struggle with hypothyroidism. We want the campaign to be a real “empowerment” tool, aimed at increasing the knowledge and awareness of hypothyroidism, at stimulating doctor-patient interaction and, above all, at disseminating an important message: the disease is not a limit, and must not preclude the possibility of leading an active and quality life.

And precisely in order to spread this message and make accessible all the information contained in the platform, IBSA created the contents of Feel Thyroid not only in English, but also in the original languages of several European geographical areas, including Italy, France, Spain, Germany, Switzerland and Poland.

IBSA Institut Biochimique SA

IBSA (Institut Biochimique SA) is a Swiss multinational pharmaceutical Company, founded in 1945 in Lugano. Today, its products are present in over 90 Countries on 5 continents, through the Company’s 17 subsidiaries located in Europe, China, and the United States. The company has a consolidated turnover of 800 million CHF, and employs over 2,000 people between headquarters, subsidiaries and production sites. IBSA holds 90 families of approved patents, plus others under development, as well as a vast portfolio of products, covering 10 therapeutic areas: reproductive medicine, endocrinology, pain and inflammation, osteoarticular, aesthetic medicine, dermatology, uro-gynaecology, cardiometabolic, respiratory, consumer health. It is also one of the largest operators worldwide in the area of reproductive medicine, and one of the world’s leaders in hyaluronic acid-based products. IBSA has based its philosophy on four pillars: Person, Innovation, Quality and Responsibility.

1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822815/#:~:text=Hypothyroidism%20affects%20up%20to%205,patients%20suffer%20from%20primary%20hypothyroidism.

2 P. Perros, L. Hegedus, E. Vezekenyi Nagy, E. Papini, H.A. Hay, J. Abad-Madronero, A.J. Tallett, M. Bilas, P. Lakwijk, A.J. Poots, The Impact of Hypothyroidism on Satisfaction with Care and Treatment and Everyday Living: Results from E-Mode Patient Self-Assessment of Thyroid Therapy, a Cross-Sectional, International Online Patient Survey, https://pubmed.ncbi.nlm.nih.gov/37134204/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005491/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Allied Telesis Launches SwitchBlade® x908 Generation 3 to Solve Enterprise and Data Center Scalability Challenges17.9.2025 11:40:00 CEST | Press release

Compact 3U modular chassis delivers capacity-on-demand flexibility and first Allied Telesis 400G support. Enterprises and data centers face mounting challenges in scaling their networks to support AI, video, IoT, and virtualized workloads. Bandwidth demand is rising, yet many organizations are held back by legacy switches, fragmented operations, and the high cost of oversized chassis systems. To address these issues, Allied Telesis today announced the SwitchBlade x908 Generation 3 (SBx908 GEN3), a next-generation modular switch that combines high-density performance, flexible interface modularity, and future-proof scalability in a compact 3U form factor. Customers can expand capacity on demand with a wide range of interface modules, tailoring the platform to their evolving requirements. Why SBx908 GEN3? The SBx908 GEN3 was developed in direct response to customer demand for scalable, space-efficient networking. Its capacity-on-demand model allows customers to start with only the ports

LTIMindtree Partners with Shopify to Launch an AI Commerce Center of Excellence17.9.2025 11:30:00 CEST | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced a partnership with Shopify, an AI powered commerce platform for enterprises that empowers businesses to launch, manage, and grow their online stores. Leveraging the Shopify platform, LTIMindtree will set up an AI enabled Center of Excellence (CoE) for Digital Commerce that will help global enterprises to transform at the speed of AI and innovate at scale. LTIMindtree Interactive, the AI-led agency unit of LTIMindtree, is driving the next wave of enterprise digital commerce transformation for CMOs across the globe. Shopify, trusted by millions of merchants, provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. Leveraging the Shopify platform, LTIMindtree will power an AI-driven Centre of Excellence to develop a best-in-class CoE that will: Build advanced AI commerce capabilities to help

Alpha’s latest report explores the impact of retail investors on fund finance provision17.9.2025 11:00:00 CEST | Press release

Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends. What does retail investment mean for subscription lines? Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants. While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed. One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-end

LatticeFlow AI Sets a New Standard for AI Governance With Evidence-Based Technical Assessments17.9.2025 10:51:00 CEST | Press release

The company introduces AI GO!, the first platform to deliver deep technical assessments across any AI system, empowering organizations to accelerate their AI advantage LatticeFlow AI, the Swiss deep-tech company advancing trustworthy and compliant AI, today announced the Early Access Program for AI GO!, the first platform that enables AI Governance Operations through deep technical assessments. With this, LatticeFlow AI sets a new standard for AI governance and compliance, enabling organizations to accelerate their AI advantage. Traditional Governance, Risk and Compliance (GRC) systems, based on checklists, are insufficient to govern complex and rapidly evolving AI systems. LatticeFlow AI GO! provides rigorous, evidence-based assessments that uncover AI risks, generate audit-ready insights, and empower confident decision-making. The platform equips AI risk and compliance teams with the visibility and confidence they need to harness the full potential of GenAI applications, chatbots, an

Seven2 and HRK LUNIS Announce Successful Double Closing17.9.2025 10:01:00 CEST | Press release

Seven2, a leading European private equity firm, and HRK LUNIS, one of the leading independent wealth managers in Germany, have successfully completed both the majority stake acquisition of HRK LUNIS by Seven2, announced in March of this year, and the merger with Grossbötzl, Schmitz & Partner, announced in April. The smooth approval process is a positive sign for the German wealth management market and underlines the stability of the sector. With the completed double closing, HRK LUNIS's client assets under management have increased to approximately €7.5 billion and the number of employees to 120. The acquisition of HRK LUNIS is Seven2’s first investment in Germany, marking a key strategic milestone to further expand the private equity firm's position in Europe. Together with Seven2, HRK LUNIS will continue its growth trajectory, further develop its product offering, and optimize its digital capabilities to drive maximum customer benefits. The company offers a broad and competitive rang

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye